Navigation Links
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Date:12/10/2012

e 2 ACE Study Design
This open-label Phase 2 trial included a total of 333 patients with relapsed or refractory AML. Data from 271 patients were reported here from the "confirmatory" phase of the study.  Data from 62 patients from an "exploratory" phase had been reported earlier.  In the "confirmatory" phase, quizartinib was investigated in two separate cohorts, and each of these cohorts was presented in separate oral sessions this week:

  • Cohort 1: Patients who are 60 years of age or older who are relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first remission of less than 12 months duration or are primary refractory to first-line chemotherapy
  • Cohort 2: Patients who are 18 years of age or older, including patients 60 years of age or older, who are relapsed or refractory after one second-line (salvage) regimen or are relapsed or refractory after HSCT

Quizartinib was administered orally, once-a-day, at a starting dose of 90 mg/day (females) or 135 mg/day (males), in 28-day treatment cycles until disease progression, elective HSCT or unacceptable toxicity that could not be mitigated with dose adjustments.  The co-primary endpoints were CRc (CR + CRp + CRi) and CR.   Additionally, partial response (PR), overall survival (OS), HSCT rates, molecular pharmacodynamic (PD) biomarkers and standard safety assessments were evaluated. 

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia (Abstract #43)
Jorge Cortes, M.D., Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Data through Sept. 28, 2012 (representing at least 10 months of follow-up f
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
3. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
6. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
7. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
8. Xstelos Holdings Announces Dividend
9. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Encision Inc. (OTCQB:ECIA), a medical device company owning ... in minimally invasive surgery, today announced financial results for ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $311 thousand, or $(0.04) per share, in the ...
(Date:7/29/2014)... Health 2.0 announces Bernard Tyson , CEO of ... Topol , Patrick Soon-Shiong , and Samsung,s President ... Fall Conference this coming Sept. 21-24 in ... set to host the very first Wearable Tech Fashion Runway ... Tech & Wearables: Powering Healthy Lifestyles. The panel will ...
(Date:7/29/2014)... July 29, 2014   ... study investigating the efficacy and safety of MSB0010718C in patients ... a rare and aggressive skin cancer lacking effective treatments   ... cohort Phase I clinical trial for the treatment of solid ... EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Satellite Dialysis Opens New Center in Merced, CA 2Satellite Dialysis Opens New Center in Merced, CA 3Satellite Dialysis Opens New Center in Merced, CA 4PDI Reports 2009 Fourth Quarter and Full Year Financial Results 2PDI Reports 2009 Fourth Quarter and Full Year Financial Results 3PDI Reports 2009 Fourth Quarter and Full Year Financial Results 4PDI Reports 2009 Fourth Quarter and Full Year Financial Results 5PDI Reports 2009 Fourth Quarter and Full Year Financial Results 6PDI Reports 2009 Fourth Quarter and Full Year Financial Results 7PDI Reports 2009 Fourth Quarter and Full Year Financial Results 8PDI Reports 2009 Fourth Quarter and Full Year Financial Results 9PDI Reports 2009 Fourth Quarter and Full Year Financial Results 10PDI Reports 2009 Fourth Quarter and Full Year Financial Results 11PDI Reports 2009 Fourth Quarter and Full Year Financial Results 12PDI Reports 2009 Fourth Quarter and Full Year Financial Results 13PDI Reports 2009 Fourth Quarter and Full Year Financial Results 14PDI Reports 2009 Fourth Quarter and Full Year Financial Results 15PDI Reports 2009 Fourth Quarter and Full Year Financial Results 16PDI Reports 2009 Fourth Quarter and Full Year Financial Results 17PDI Reports 2009 Fourth Quarter and Full Year Financial Results 18PDI Reports 2009 Fourth Quarter and Full Year Financial Results 19PDI Reports 2009 Fourth Quarter and Full Year Financial Results 20PDI Reports 2009 Fourth Quarter and Full Year Financial Results 21PDI Reports 2009 Fourth Quarter and Full Year Financial Results 22PDI Reports 2009 Fourth Quarter and Full Year Financial Results 23PDI Reports 2009 Fourth Quarter and Full Year Financial Results 24PDI Reports 2009 Fourth Quarter and Full Year Financial Results 25PDI Reports 2009 Fourth Quarter and Full Year Financial Results 26PDI Reports 2009 Fourth Quarter and Full Year Financial Results 27PDI Reports 2009 Fourth Quarter and Full Year Financial Results 28PDI Reports 2009 Fourth Quarter and Full Year Financial Results 29PDI Reports 2009 Fourth Quarter and Full Year Financial Results 30PDI Reports 2009 Fourth Quarter and Full Year Financial Results 31PDI Reports 2009 Fourth Quarter and Full Year Financial Results 32PDI Reports 2009 Fourth Quarter and Full Year Financial Results 33
(Date:7/29/2014)... 29, 2014 Award-winning inventor Michael Croix has ... neutralizer specifically designed to absorb embarrassing odors in the office. ... easily be stored in a desk drawer. This compact packaging ... users will simply sit on the pad and poof away! ... office and then BAM, someone appears out of nowhere. It’s ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Riverdale Urgent ... what they do. Through their presence at local events, ... to be more than just a medical service for ... Care donated money in support of Riverdale RiverFest and ... community event that features local musicians and entertainers, arts ...
(Date:7/29/2014)... Lean and Lovely, an affordable and short program, claims ... wear a bikini in the near future. This has caught ... , “Our Lean and Lovely review shows that ... levels. Neither your age nor your body shape matters, which ... the beginning, you will achieve the results that you have ...
(Date:7/29/2014)... AZ (PRWEB) July 29, 2014 Current ... was prescribed pain medication post foot surgery during his first ... time in foot surgery – twice on one foot, once ... prescription drugs. “I broke my foot a year ago and ... was recommended to Jon by a friend from home who’d ...
(Date:7/29/2014)... PeopleKeys today announced that they are launching a ... train and certify others in applied DISC behavioral analysis. ... will be taught by PeopleKeys Master Coach Dan Mucci ... a live Tele-course over the span of 10 weeks ... Trainer course will use a combination of real-time online ...
Breaking Medicine News(10 mins):Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 2Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 3Health News:Lean and Lovely: Review Examining Neghar Fonooni’s Program Released 2Health News:Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety 2Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 2Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 3
... Nile Therapeutics, Inc., (Nasdaq: NLTX ), announced today ... 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, ... The Westin St. Francis Hotel in San Francisco, CA. ... clinical development programs for its lead compound, CD-NP, a novel ...
... Antonio Villaraigosa, Cal State LA President James Rosser, ... for the construction dedication ceremony of its new ... SA (Grifols), a global healthcare company based in ... Villaraigosa., Cal State LA President James Rosser, Councilman ...
... 50 labor organizations, including United Healthcare Workers and the ... to overturn ban on same-sex marriageOAKLAND, Calif., Jan. 13 ... organizations, including United Healthcare Workers (UHW) and the California ... support of the three lawsuits now challenging Proposition 8, ...
... prescribing of cholesterol-lowering drugs, experts say , , ... start taking results of a recent drug company-sponsored ... be taking cholesterol-lowering statin medications, experts say. , ... in November 2008. The study was cut short, ...
... Tricyclic medications helped with pain, fatigue and depression, ... -- Antidepressants may help people living with the ... improve their quality of life, new research shows. ... of Klinikum Saarbrucken in Germany, found that fibromyalgia ...
... Then warm up - and protect yourself from the dangers ... temperatures are hitting most of the country this week, but ... long winter months. If you do go outside for some ... yourself from frostbite . When body tissues are frostbitten, ...
Cached Medicine News:Health News:Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Health News:Grifols Celebrates Initial Construction of New IVIG Facility with Los Angeles Officials and Dignitaries 2Health News:Calif. Labor Unions Unite to Fight Prop 8 2Health News:Millions More Americans Might Be Placed on Statins 2Health News:Millions More Americans Might Be Placed on Statins 3Health News:Is Jack Frost Nipping At Your Nose? 2Health News:Is Jack Frost Nipping At Your Nose? 3
6.5mm diameter handpiece; 75mm handle with grooves for grip; Standard male luer taper fits most cannula hub and female luer taper....
Hook Shaped Tip , Curved to the Left; with 30 cm long silicone tubing with connector; overall length 40mm; stainless steel...
... forceps are designed for endomyocardial biopsies. ... a 3-pull ring handle, stainless steel cutting jaws, ... rotates to accommodate any position. ,A spring in ... jaws are opened by moving the double rings ...
The only solution for in-line digital measurement...
Medicine Products: